Copyright
©The Author(s) 2018.
World J Gastroenterol. May 14, 2018; 24(18): 2024-2035
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.2024
Published online May 14, 2018. doi: 10.3748/wjg.v24.i18.2024
Table 1 Patients’ characteristics n %
Characteristic | No fibrosis,n = 23 | Liver fibrosis,n = 50 | All,n = 73 |
Age in yr | 39.5 ± 11.1 | 41.3 ± 12.5 | 40.8 ± 12.1 |
Sex | |||
Male | 17 (74) | 30 (60) | 47 (64) |
Female | 6 (26) | 20 (40) | 26 (36) |
Height in m | 1.72 ± 0.09 | 1.70 ± 1.21 | 1.71 ± 1.15 |
Weight in kg | 77.21 ± 17.32 | 78.23 ± 16.12 | 78.10 ± 16.64 |
BMI in kg/m2 | 24.09 ± 4.91 | 22.06 ± 4.57 | 23.73 ± 4.65 |
CHB | 21 (34) | 41 (66) | 62 (85) |
CHC | 2 (18) | 9 (82) | 11 (15) |
Table 2 Pre, Post, reduction rate of T1 relaxation time, and hepatocyte fraction (%) of patients at different METAVIR fibrosis stages
Fibrosis stage, (METAVIR) | F0, n = 23 | F1, n = 19 | F2, n = 13 | F3, n = 6 | F4, n = 12 | Total, n = 73 |
Mean pre-T1 liver | 180 ± 28 | 188 ± 19 | 174 ± 17 | 192 ± 22 | 200 ± 24 | 186 ± 24 |
Mean post-T1 liver | 356 ± 44 | 355 ± 38 | 316 ± 34 | 336 ± 43 | 305 ± 50 | 338 ± 46 |
RE | 0.94 ± 0.18 | 0.89 ± 0.20 | 0.94 ± 0.16 | 0.71 ± 0.17 | 0.52 ± 0.15 | 0.84 ± 0.23 |
HeF (%) | 88.77 ± 5.10 | 84.23 ± 6.99 | 79.71 ± 8.09 | 70.90 ± 7.27 | 62.80 ± 7.01 | 80.24 ± 11.30 |
Table 3 Correlation of reduction rate of T1 relaxation time, hepatocyte fraction, and METAVIR fibrosis stages
Pre | Post | RE | HeF | |
r (95%CI) | 0.188 (-0.045 to 0.4003) | -0.525 (-0.674 to 0.336) | -0.773 (-0.852 to 0.661) | -0.808 (-0.875 to 0.709) |
P value | 0.112 | 0.001 | < 0.001 | < 0.001 |
Table 4 Performance of the mean reduction rate of T1 relaxation time and hepatocyte fraction for the prediction of METAVIR fibrosis stages according to cut-off values
Parameters | ≥ F1 | ≥ F2 | ≥ F3 | = F4 |
Cut-off | ||||
HeF (%) | 82.93 | 79.24 | 74.37 | 74.37 |
RE | 0.75 | 0.73 | 0.72 | 0.72 |
AUC | ||||
HeF (%) | 0.837 (0.733-0.913) | 0.890 (0.795-0.951) | 0.957 (0.881-0.990) | 0.957 (0.882-0.991) |
RE | 0.678 (0.559-0.783) | 0.723 (0.606-0.821) | 0.921 (0.834-0.971) | 0.962 (0.889-0.993) |
Sensitivity, % | ||||
HeF(%) | 72.0 (57.5-83.8) | 77.4 (58.9-90.4) | 94.4 (72.7-99.9) | 100.0 (73.5-100.0) |
RE | 44.0 (30.0-58.7) | 58.1 (39.1-75.5) | 88.9 (65.3-98.6) | 100.0 (73.5-100.0) |
Specificity, % | ||||
HeF (%) | 82.6 (61.2-95.0) | 92.9 (80.5-98.5) | 92.7 (82.4-98.0) | 85.3 (73.8-93.0) |
RE | 100.0 (85.2-100.0) | 92.9 (80.5-98.5) | 92.7 (82.4-98.0) | 86.9 (75.8-94.2) |
PPV, % | ||||
HeF (%) | 90.0 (76.3-97.2) | 88.9 (70.8-97.6) | 81.0 (58.1-94.6) | 57.1 (34.0-78.2) |
RE | 100.0 (84.6-100.0) | 85.7 (63.7-97.0) | 80.0 (56.3-94.3) | 60.0 (36.1-80.9) |
NPV, % | ||||
HeF (%) | 57.6 (39.2-74.5) | 84.8 (71.1-93.7) | 98.1 (89.7-100.0) | 100.0 (93.2-100.0) |
RE | 45.1 (31.1-59.7) | 75.0 (61.1-86.0) | 96.2 (87.0-99.5) | 100.0 (93.3-100.0) |
PLR | ||||
HeF (%) | 4.14 (1.7-10.3) | 10.84 (3.6-32.8) | 12.99 (5.0-33.6) | 6.78 (3.7-12.4) |
RE | _ | 8.13 (2.6-25.2) | 12.22 (4.7-31.8) | 7.62 (4.0-14.5) |
NLR | ||||
HeF (%) | 0.34 (0.2-0.5) | 0.24 (0.1-0.5) | 0.060 (0.009-0.4) | _ |
RE | 0.56 (0.4-0.7) | 0.45 (0.3-0.7) | 0.12 (0.03-0.4) | _ |
- Citation: Pan S, Wang XQ, Guo QY. Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging. World J Gastroenterol 2018; 24(18): 2024-2035
- URL: https://www.wjgnet.com/1007-9327/full/v24/i18/2024.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i18.2024